Evidence map›Paper›PMID 34374812›Full record

ArticleCancer immunology, immunotherapy : CII2022

The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.

Pin-Jui Kung, Ting-Yu Lai, Jerry Cao, Li-Chung Hsu, Tsai-Chen Chiang, Pu Ou-Yang, Ching-Yi Tsai, Yi-Fen Tsai, Chih-Wen Lin, Chien-Chia Chen and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Pin-Jui KungDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Ting-Yu LaiInstitute of Molecular Medicine, College of Medicine, National Taiwan University, No. 1 Jen-Ai Road, Sec. 1, Taipei, 10002, Taiwan.
Jerry CaoDepartment of Surgery, Wollongong Hospital, Loftus Street, Wollongong, NSW, 2500, Australia.
Li-Chung HsuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, No. 1 Jen-Ai Road, Sec. 1, Taipei, 10002, Taiwan.
Tsai-Chen ChiangDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Pu Ou-YangDepartment of Medical Research, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Ching-Yi TsaiDepartment of Medical Research, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Yi-Fen TsaiDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Chih-Wen LinDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, and School of Medicine, College of Medicine, I-Shou University, No. 1, Sec. 1, Syuecheng Road, Dashu District, Kaohsiung City, 84001, Taiwan.
Chien-Chia ChenDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Meng-Kun TsaiDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Yu-Wen TienDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Chih-Yuan LeeDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan. gs2119@gmail.com.ORCID http://orcid.org/0000-0001-5034-3544
National Taiwan University Hospital · TWNational Taiwan University · TWI-Shou University · TWWollongong Hospital · AU

Funding

Ministry of Science and Technology, Taiwan 109-2314-B-002-080Ministry of Science and Technology, Taiwan 109-2326-B002-003
6 · The paper itself

Abstract

backgroundA major feature of the microenvironment in pancreatic ductal adenocarcinoma (PDAC) is the significant amount of extracellular matrix produced by pancreatic stellate cells (PSCs), which have been reported to enhance the invasiveness of pancreatic cancer cells and negatively impact the prognosis.

methodsWe analyzed the data from two publicly available microarray datasets deposited in the Gene Expression Omnibus and found candidate genes that were differentially expressed in PDAC cells with metastatic potential and PDAC cells cocultured with PSCs. We studied the interaction between PDAC cells and PSCs in vitro and verified our finding with the survival data of patients with PDAC from the website of The Human Protein Atlas.

resultsWe found that PSCs stimulated PDAC cells to secrete S100A9, which attracted circulatory monocytes into cancer tissue and enhanced the expression of programmed death-ligand 1 (PD-L1) on macrophages. When analyzing the correlation of S100A9 and PD-L1 expression with the clinical outcomes of patients with PDAC, we ascertained that high expression of S100A9 and PD-L1 was associated with poor survival in patients with PDAC.

conclusionsPSCs stimulated PDAC cells to secrete S100A9, which acts as a chemoattractant to attract circulatory monocytes into cancer microenvironment and induces expression of PD-L1 on macrophages. High expression of S100A9 and PD-L1 was associated with worse overall survival in a cohort of patients with PDAC.

Indexed as

Cell CommunicationBiomarkersCalgranulin BCancer-Associated FibroblastsCarcinoma, Pancreatic DuctalCell Line, TumorCell MovementCoculture TechniquesCulture Media, ConditionedDisease SusceptibilityGene Expression ProfilingGene Expression Regulation, NeoplasticGene SilencingHumansNeoplasm GradingNeoplasm StagingBiomarkersCalgranulin BCulture Media, ConditionedS100A9 protein, humanPancreatic ductal adenocarcinomaPD-L1PSCS100A9

Identifiers

PMID34374812
PMCPMC8854169
OpenAlexW3187798721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.